TriSalus Life Sciences Inc
For the period ended Dec 31, 2023. Filed Apr 11, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Apr 11, 2024
TLSI$2.85-11.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ Equity
CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ DEFICIT
(in thousands, except share data)
| Preferred stock · Common stock · Additionalpaid-incapital · Accumulateddeficit · TotalStockholders’Equity (Deficit) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares · Amount · Shares · Amount | ||||||||||||
| At December 31, 2021 | — | $— | 264,978 | $— | $6,737 | $(136,342) | $(129,605) | |||||
| Exercise of options | — | — | 82,879 | — | 94 | — | 94 | |||||
| Exercise of common stock warrants | — | — | 69 | — | — | — | — | |||||
| Share-based compensation | — | — | — | — | 368 | — | 368 | |||||
| Deemed dividend | — | — | — | — | 2,829 | (2,829) | — | |||||
| Net loss | — | — | — | — | — | (47,187) | (47,187) | |||||
| At December 31, 2022 | — | $— | 347,926 | $— | $10,028 | $(186,358) | $(176,330) | |||||
| Exercise of options | — | — | 247,612 | — | 180 | — | 180 | |||||
| Share-based compensation | — | — | — | — | 1,402 | — | 1,402 | |||||
| Deemed dividend | — | — | — | — | 2,981 | (2,981) | — | |||||
| Impact of Business Combination | ||||||||||||
| Conversion of redeemable convertible preferred stock into common stock in connection with the Business Combination | — | — | 21,500,867 | 2 | 204,234 | — | 204,236 | |||||
| Assumption of warrants to purchase common stock in connection with the Business Combination | — | — | — | — | (2,568) | — | (2,568) | |||||
| Issuance of common stock upon closing the Business Combination, net of expenses | — | — | 4,316,808 | — | 957 | — | 957 | |||||
| Contingent earnout liability recognized upon closing of the Business Combination | — | — | — | — | (28,927) | — | (28,927) | |||||
| Assumption of preferred stock in connection with the Business Combination | 4,015,002 | — | — | — | 34,150 | — | 34,150 | |||||
| Net loss | — | — | — | (59,038) | (59,038) | |||||||
| At December 31, 2023 | 4,015,002 | $— | 26,413,213 | $2 | $222,437 | $(248,377) | $(25,938) | |||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.